ワンダーカジノ入金不要ボーナス News Release

Top
News

Latest News

May 26, 2010: New Medium-Term Business Plan Developed: ワンダーカジノ入金不要ボーナス;HOPE 100 Stage 1ワンダーカジノ入金不要ボーナス;
February 3, 2010: Third Quarter Consolidated Financial Results ワンダーカジノ入金不要ボーナス Fiscal Year Ending March 31, 2010
January 18, 2010: MARKETING APPROVAL FOR ワンダーカジノ入金不要ボーナス;MUCODYNE® DS50%ワンダーカジノ入金不要ボーナス;
January 7, 2010: Application filed for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder
November 5, 2009: ワンダーカジノ入金不要ボーナス Neramexane for Tinnitus with Merz Pharmaceuticals for Japan Territory
September 29, 2009: KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries
August 5, 2009: First Quarter Consolidated Financial Results ワンダーカジノ入金不要ボーナス Fiscal Year Ending March 31, 2010
July 27, 2009: Grant of Marketing Right to Senju Pharmaceutical on Gatifloxacin Ophthalmic Solution in China
April 3, 2009: Change of Representative Director and President at ワンダーカジノ入金不要ボーナス
April 3, 2009: Change of Representative Director and President at KYORIN
ワンダーカジノ入金不要ボーナス9, 2009: KYORIN Announces Dissolution of Subsidiary
ワンダーカジノ入金不要ボーナス9, 2009: KYORIN Subsidiary (Investment LPS) to Be Dissolved
February 27, 2009: ワンダーカジノ入金不要ボーナス Licensing and Supply Agreement on Uritos® Tablets with SPIMACO
February 5, 2009: Third Quarter Consolidated Financial Results ワンダーカジノ入金不要ボーナス Fiscal Year Ending March 31, 2009
February 4, 2009: KYORIN Updates Credit Rating from ワンダーカジノ入金不要ボーナス;I
January 29, 2009: Paper on Clinical Trial of MUCODYNE® for COPD Patients (PEACE Study) Chosen ワンダーカジノ入金不要ボーナス LANCET Paper of the Year 2008
December 24, 2008: Approval for an additional regimen and dose of Pentasa®ワンダーカジノ入金不要ボーナス treatment of ulcerative colitis in its active phase
October 1, 2008: Launch of Ulcerative Colitis and Crohn's Disease Therapeutic Agent Pentasa Tablets 500
September 30, 2008: Discontinuation of Commercialization of Gatiflo(gatifloxacin) Tablets, a broad-spectrum antibacterial agent, in Japan
August 20, 2008: Results of Overseas Clinical Studies for KRP-104, anti-diabetes agent
April 22, 2008: ワンダーカジノ入金不要ボーナス Flutiform, an Anti-asthmatic Treatment, in Japan
April 18, 2008: Launch of KIPRES Tablets 5mg
March 3, 2008: Pentasa Tablets 250 Received Approvals For Additional Pediatric Indication
February 21, 2008: Results of Analysis of the OASIS Study,a Large-Scale Health-Related QOL Study in Patients with Chronic Cerebral Infarction
January 30, 2008: ワンダーカジノ入金不要ボーナス an Exclusive Patent License and Collaborative Research and Development Agreement with Merck & Co.,Inc. in the Field of Infectious Diseases
January 25, 2008: KIPRES Received Approvals for Additional Indication to Relieve Symptoms of Allergic Rhinitis
December 26, 2007: KYORIN Obtains Credit Rating from ワンダーカジノ入金不要ボーナス;I
October 12, 2007: Discontinuation of Cooperation on Baynas Marketing for Treatment of Allergic Rhinitis by ワンダーカジノ入金不要ボーナス.,Ltd. and Bayer Yakuhin,Ltd.
October 2, 2007: Launch of ワンダーカジノ入金不要ボーナス;KIPRESワンダーカジノ入金不要ボーナス; Oral Granules 4mg
September 26, 2007: Merger between Kyorin Phamaceutical Co.,Ltd. and Nisshin ワンダーカジノ入金不要ボーナス.,Ltd.
July 31, 2007: Marketing Approval for ワンダーカジノ入金不要ボーナス;KIPRESワンダーカジノ入金不要ボーナス; Oral Granules 4mg
April 28, 2006: Kyorin Licensee Announces Decision to Stop Commercialization of Tequin
ワンダーカジノ入金不要ボーナス0, 2006: On the Transition to a Holding - Company Structure
ワンダーカジノ入金不要ボーナス0, 2006: On Kyorin ワンダーカジノ入金不要ボーナスing and the establishment of a New Corporate Mark & Logotype